Airway epithelial cells (AECs) play a key role in asthma susceptibility and severity. 25 Integrin β4 (ITGB4) is a structural adhesion molecule that is downregulated in the 26 airway epithelium of asthma patients. Specific ITGB4 deficiency in AECs induces 27 exaggerated Th2 responses, severe allergen-induced airway inflammation and airway 28 hyperresponsiveness (AHR) in mouse model of allergic asthma. However, the 29 underlying mechanisms remain unexplored. In this study, we determine the role of 30 ITGB4 of AECs in the regulation of Th2 response and in the induction of asthma and 31 identify the underpinning molecular mechanisms. We found that ITGB4 deficiency 32 led to exaggerated Th2 cells infiltration, inflammation and AHR and higher 33 production of CCL17 in HDM treated mice. ITGB4-regulated CCL17 production in 34 AECs was regulated by EGFR, ERK and NF-κB pathways. EFGR-antagonist 35 treatment or the neutralization of CCL17 by antibody inhibited exaggerated 36 pathological marks in HDM-challenged ITGB4-deficient mice. Together, these results 37 demonstrated that ITGB4 of AECs negatively regulates the development of Th2 38 responses of allergic asthma by down-regulation of EGFR and CCL17 pathway.
Introduction 41
Airway epithelial cells (AECs) form a barrier to environment hazardous stimuli by 42 tight intercellular junctions and adhesion on basal membrane (Roche et al, 1993) . of both ITGB4 +/+ and ITGB4 -/groups following HDM exposure as compared to 143 respective PBS control groups, and the levels of CD4 + IFN- + T cells did not display 144 significant changes (Fig 2A) . Of note, the infiltration of Th2 and Th17 cells were 145 significantly greater in HDM exposed ITGB4 -/animals than that of ITGB4 +/+ animals. 146 Likewise, the protein and transcript levels of IL-4, IL-5, IL-13 and IL-17A were 147 significantly elevated as demonstrated in the BALF of HDM exposed ITGB4 -/group, 148 when compare to those of HDM exposed ITGB4 +/+ group (Fig 2B and C) . HDM 149 exposure resulted in significantly increased levels of these cytokines in BALF and 150 lung of ITGB4 +/+ mice, as compared to those PBS exposed control. These data 151 provide evidence that ITGB4 negatively regulates the activity of Th2 and Th17 cells 152 but not Th1 cells.
153
ITGB4 negatively impacts on CCL17 production 154 Both clinic and animal studies have shown that Th2 cells orchestrate the development 155 of allergic asthma (KleinJan, 2015) . To determine how ITGB4 contributes the 156 activation of Th2 cells, we examined the levels of CCL3, CCL5, CCL17 and CCL22 asthma and healthy subjects were also collected to determine the secretion of CCL17. 165 By using ELISA, levels of CCL17 were found significantly higher in the sputum of 166 patients with allergic asthma, as compared to that of healthy controls ( Fig 3C) . Taken 167 together, these findings indicate that ITGB4 in AECs critically regulates the 168 expression of CCL17 and is associated with the pathogenesis of allergic asthma. AECs was higher than that in ITGB4 +/+ AECs in the absence of EGF ( Fig 4A) .
177
However, EGF significantly enhanced EGFR phosphorylation in ITGB4 -/-AECs, as 178 compared to that in ITGB4 +/+ AECs. Furthermore, assays with immunoprecipitation 179 ( Fig 4B) and immunofluorescence ( Fig 4C) revealed a direct binding between ITGB4 180 and EGFR in cultured AECs. These results suggest that ITGB4 negatively regulates 181 EGFR phosphorylation through physical association with the receptor.
182

ITGB4 regulates the production of CCL17 through the activation of EGFR,
183
ERK and NF-κB pathways 184 To determine the role of EGFR mediated signaling pathways in ITGB4-regulated 185 CCL17 production, we examined the expression of CCL17 in isolated AECs using multiple inhibitors, including AG1478 for EGFR phosphorylation, U0126 for ERK1/2 187 phosphorylation and SC75741 for NF-κB p65 activation. Western blot analysis 188 revealed that treatments with AG1478, U0126 or SC75741 significantly inhibited the 189 levels of p-EGFR, p-ERK1/2 or nucleus NF-κB p65 in ITGB4 -/-AECs than those in 190 ITGB4 +/+ AECs, respectively ( Fig 5A, B and C). Importantly, these inhibitor 191 treatments blocked heightened CCL17 production in ITGB4 -/-AECs. ERK activated 192 pathways has been described to induce phosphorylation and translocation of the 193 transcription factor NF-κB to the nucleus (37). Meanwhile, NF-κB inhibitors have 194 been reported to block CCL17 expression in the alveolar epithelial cell line (Berin et 195 al, 2001) . To verify the possible involvement of NF-κB in the upregulation of CCL17, 196 we studied p65 subunit of the active NF-κB complex upon stimulation with AG1478, 197 U0126 or SC75741. As anticipated, treatments with AG1478, U0126 and SC75741 198 reduced the levels of nucleus NF-κB p65 whose binding sites are present in the 199 CCL17 promoter in ITGB4 -/-AECs ( Fig 5D) . Together, these findings indicate that 200 blocking EGFR, ERK and NF-κB pathways suppresses augmented CCL17 production 201 in ITGB4 -/-AECs following HDM exposure.
202
Blockade of EGFR phosphorylation inhibits CCL17 production and exaggerated
203
AHR, airway inflammation and Th2 cells infiltration 204
To investigate the role of EGFR signaling pathway in ITGB4-regulated CCL17 205 production, we blocked EGFR phosphorylation with AG1478 both in vitro and in vivo 206 by using ITGB4 -/-AECs and mice. Administration of AG1478 inhibited the levels of 207 p-EGFR in AECs, as compared to vehicle treatment ( Fig 6A) . Furthermore, inhibition 208 of EGFR phosphorylation by AG1478 led to significantly decreased levels of CCL17 209 in cultured ITGB4 -/-AECs ( Fig 6B) . Exaggerated AHR and histopathological scores 210 were also significantly reduced by EGFR blockade in HDM exposed ITGB4 -/mice, 211 as compared to those of vehicle treatment ( Fig 6C and D) . Flow cytometry revealed 212 that AG1478 administration significantly reduced the levels of IL-4 + CD4 + T cells and 213 IL-13 + CD4 + T cells but not IFN- + CD4 + T cells and IL-17 + CD4 + T cells in the lung 214 of HDM treated ITGB4 -/mice ( Fig 6E) . These data suggest that EGFR signaling 215 pathway underpins ITGB4-regulated CCL17 production in AECs and thus contributes 216 to the pathogenesis of Th2 inflammation.
217
Neutralization of CCL17 diminishes exaggerated AHR, airway inflammation and 218
Th2 responses in HDM exposed ITGB4 -/mice 219 As a key role for CCL17 is indicated in the pathogenesis, we neutralized this 220 chemokine with anti-CCL17 mAb in HDM exposed ITGB4 -/mice. Treatment with 221 anti-CCL17 mAb significantly and greatly decreased the levels the chemokine in 222 lung, as compared to isotype Ab treatment ( Fig 7A) . Neutralization of CCL17 223 significantly suppressed exaggerated AHR, airway inflammation in HDM exposed 224 ITGB4 -/mice ( Fig 7B and C) . Of note, anti-CCL17 mAb treatment reduced the levels 225 of CD4 + IL-4 + T cells and CD4 + IL-13 + T cells but not CD4 + IFN- + T cells and 226 CD4 + IL-17 + T cells in the lung of HDM exposed ITGB4 -/mice ( Fig 7D) . Similarly, 227 neutralizing CCL17 decreased the protein and transcript levels of IL-4, IL-5, and IL-228 13, but not those of IFN- and IL-17A in the BALF and lung of HDM exposed 229 ITGB4 -/mice, as compared to isotype Ab treatment ( Fig 7E and F) . other CCR4-binding chemokines (e.g. CCL3, CCL5 and CCL22) did not show 268 significant differences, the level of CCL17 was significantly elevated in the BALF 269 and the lung of HDM exposed ITGB4 -/mice (Fig 3) . Notably, a significantly 270 increased level of CCL17 was detected in the sputum of allergic asthma patients. phosphorylation of EGFR and reduced CCL17 production in the AECs of HDM 297 exposed ITGB4 -/mice to basal level. It also significantly inhibited the development 298 of AHR, airway inflammation and the infiltration of Th2 cells (Fig 6) . Furthermore, 299 neutralizing CCL17 dramatically suppressed the manifestation of the disease in our 300 model. Therefore, our data have shown that EGFR and CCL17 critically contribute to 301 the disease, as demonstrated by its' impact on Th2 cells infiltration, exaggerated AHR, 302 airway inflammation in HDM exposed ITGB4 -/mice. 303 Interestingly, we have also found that ITGB4 defect leads to heightened 304 infiltration of Th17 cells and higher production of IL-17A (Fig 2) . The importance of were not affected after EGFR-inhibitor or anti-CCL17 mAb treatments in HDM 317 exposed ITGB4 -/mice, suggesting a specific role of ITGB4 in the pathophysiology of allergic asthma by the regulation of Th2 and Th17 responses.
319
In conclusion, our data provide an insight that ITGB4 defect in AECs leads to 
336
The demographic and clinical characteristics are shown in Table EV1 . Induced Immunofluorescent staining was also performed on primary mouse AECs 393 using the following antibodies: anti-ITGB4 (Ab182120, Abcam), anti-EGFR 
